Publication
Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study.
Journal Paper/Review - Jul 20, 2024
Rubbert-Roth Andrea, Kato Koji, Haraoui Boulos, Rischmueller Maureen, Liu Yanxi, Khan Nasser, Camp Heidi S, Xavier Ricardo M
Units
PubMed
Doi
Contact
Citation
Rubbert-Roth A, Kato K, Haraoui B, Rischmueller M, Liu Y, Khan N, Camp H, Xavier R. Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study. Rheumatol Ther 2024; 11:1197-1215.
Type
Journal Paper/Review (English)
Journal
Rheumatol Ther 2024; 11
Publication Date
Jul 20, 2024
Issn Print
2198-6576
Pages
1197-1215
Brief description/objective
The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term extension (LTE) of the phase 3 SELECT-CHOICE study.